Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Feb 18;9(1):47-54.
doi: 10.1159/000536281. eCollection 2024 Jan-Dec.

Dietary Perceptions among Patients with Crohn's Disease in Clinical Remission: Comparison with an Era Preceding the Availability of Biologic Therapy

Affiliations

Dietary Perceptions among Patients with Crohn's Disease in Clinical Remission: Comparison with an Era Preceding the Availability of Biologic Therapy

Makoto Tanaka et al. Inflamm Intest Dis. .

Abstract

Introduction: Dietary temperance significantly affects the quality of life of patients with Crohn's disease (CD) and remains a major concern. However, perceptions of diet in remission may have changed from the era when treatment options were limited. Therefore, we compared the dietary perceptions and treatment of patients with CD in remission with previously published data from the time biologic therapy was not introduced.

Methods: We compared the data of 254 patients with CD in remission who completed a questionnaire survey in 2022 with those of 76 patients with CD in remission collected in 2003, when biologics were not used for maintenance therapy in Japan. Remission was defined as a CD activity index of 150 or less in both studies. Perceptions of diet (degree of eating whatever one likes) were assessed using single-item nominal scale responses.

Results: The percentage of patients receiving enteral nutrition therapy had decreased (past vs. present: 43.4 vs. 12.6%), while the proportion of patients receiving biologic therapy increased (0 vs. 88.6%, respectively). The percentages of patients who responded "not at all," "sometimes," and "mostly" when asked if they could eat whatever they liked had changed, respectively, from 9.2%, 46.1%, and 44.7% in the past to 4.3%, 25.2%, and 70.5% in the present.

Conclusion: The proportion of those who ate whatever they liked and the mean body mass index increased in comparison with the corresponding values 20 years ago. With the advent of biologic therapies, the number of patients with CD who can enjoy eating has increased.

Keywords: Biologics; Crohn’s disease; Dietary perceptions; Food avoidance; Maintenance of remission; Restrictive eating.

PubMed Disclaimer

Conflict of interest statement

Makoto Tanaka received lecture fees from Takeda Pharmaceutical and Mitsubishi Tanabe Pharma and received collaborative research funds from Takeda Pharmaceutical. Aki Kawakami has no conflicts of interest to declare. Kayoko Sakagami received lecture fees from Takeda Pharmaceutical, Mochida Pharmaceutical, Janssen Pharmaceutical, AbbVie, Pfizer, EA Pharma, Zeria Pharmaceutical, and Gilead Sciences. Hiroaki Ito received lecture fees from Takeda Pharmaceutical, Mitsubishi Tanabe Pharma, Janssen Pharmaceutical, AbbVie, Mochida Pharmaceutical, Pfizer, EA Pharma, Zeria Pharmaceutical, Nippon Kayaku, Gilead Sciences, Kyorin Pharmaceutical, and Nippon Shinyaku.

Similar articles

Cited by

References

    1. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE. ACG clinical guideline: management of Crohn’s disease in adults. Am J Gastroenterol. 2018;113(4):481–517. - PubMed
    1. Hou JK, Abraham B, El-Serag H. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am J Gastroenterol. 2011;106(4):563–73. - PubMed
    1. Goens D, Micic D. Role of diet in the development and management of Crohn’s disease. Curr Gastroenterol Rep. 2020;22(4):19. - PubMed
    1. Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, et al. . Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol. 2021;56(6):489–526. - PMC - PubMed
    1. Gomollon F, Dignass A, Annese V, Tilg H, Van Assche G, Lindsay JO, et al. . 3rd European evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: Part 1: diagnosis and medical management. J Crohns Colitis. 2017;11(1):3–25. - PubMed